World Investment Advisors Sells 5,480 Shares of Abbott Laboratories $ABT

World Investment Advisors lessened its holdings in Abbott Laboratories (NYSE:ABT) by 8.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 57,391 shares of the healthcare product maker’s stock after selling 5,480 shares during the quarter. World Investment Advisors’ holdings in Abbott Laboratories were worth $5,892,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. 4WEALTH Advisors Inc. boosted its position in Abbott Laboratories by 32.8% in the 1st quarter. 4WEALTH Advisors Inc. now owns 7,597 shares of the healthcare product maker’s stock valued at $774,000 after buying an additional 1,875 shares during the period. Sierra Summit Advisors LLC increased its position in shares of Abbott Laboratories by 14.3% during the first quarter. Sierra Summit Advisors LLC now owns 4,002 shares of the healthcare product maker’s stock worth $411,000 after acquiring an additional 502 shares during the period. Y Intercept Hong Kong Ltd bought a new stake in shares of Abbott Laboratories during the first quarter valued at approximately $2,964,000. Leonteq Securities AG boosted its holdings in shares of Abbott Laboratories by 5,789.3% in the first quarter. Leonteq Securities AG now owns 16,490 shares of the healthcare product maker’s stock valued at $1,693,000 after purchasing an additional 16,210 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund grew its stake in Abbott Laboratories by 61.4% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 884,654 shares of the healthcare product maker’s stock worth $90,827,000 after purchasing an additional 336,450 shares in the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. Mizuho cut their price target on Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a research note on Friday, April 17th. Benchmark lowered their price objective on shares of Abbott Laboratories from $145.00 to $120.00 and set a “buy” rating for the company in a research note on Friday, April 17th. Weiss Ratings cut shares of Abbott Laboratories from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, June 16th. The Goldman Sachs Group reduced their price target on shares of Abbott Laboratories from $121.00 to $113.00 and set a “buy” rating for the company in a report on Wednesday, May 27th. Finally, Wells Fargo & Company lowered their price target on shares of Abbott Laboratories from $122.00 to $109.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Three equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.42.

Abbott Laboratories Stock Performance

Shares of Abbott Laboratories stock opened at $95.25 on Friday. The company has a market capitalization of $165.91 billion, a PE ratio of 26.68, a P/E/G ratio of 1.64 and a beta of 0.61. The company has a 50-day simple moving average of $88.95 and a two-hundred day simple moving average of $104.35. Abbott Laboratories has a one year low of $81.97 and a one year high of $137.49. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.01 and a current ratio of 1.39.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.14 by $0.01. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm had revenue of $11.16 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the firm earned $1.09 EPS. The company’s quarterly revenue was up 7.8% compared to the same quarter last year. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Research analysts expect that Abbott Laboratories will post 5.48 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 17th. Investors of record on Wednesday, July 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is 70.59%.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau acquired 2,200 shares of the firm’s stock in a transaction on Thursday, April 23rd. The stock was acquired at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the purchase, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction dated Monday, April 27th. The stock was acquired at an average price of $92.65 per share, for a total transaction of $926,500.00. Following the purchase, the director directly owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This trade represents a 0.15% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. 0.46% of the stock is owned by corporate insiders.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.